Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112

23 Feb. 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced the first patient dose has been completed with next-generation EGFR Exon20ins inhibitor ABSK112 for non-small cells lung cancer (NSCLC).

ABSK112 has received clinical study approval from the China NMPA and U.S. FDA, and the Phase I studies were conducted simultaneously in the United States and China.

ABSK112 is a next-generation oral EGFR Exon20ins inhibitor with high potency, high selectivity, and strong brain penetrating ability. In comparison to previously approved and clinically studied 1st generation EGFR Exon20ins inhibitors, ABSK112 in preclinical studies has demonstrated excellent brain penetrating ability, superior selectivity over wild type EGFR, broader spectrum of Exon20ins mutation coverage, and superior in vivo efficacy in various EGFR Exon20ins xenograft models. These findings highlight ABSK112's potential in providing an improved therapeutic window and enhanced efficacy in clinic, positioning it as a next-generation potential best-in-class EGFR Exon20ins inhibitor.

About NSCLC

Lung cancer is the second most common cancer worldwide, with more than two million new cases in 2020, including 227,875 cases in U.S. and 815,563 cases in China, respectively. It ranks first in terms of mortality, with more than 1.7 million deaths per year, including 138,225 cases in U.S. and 714,699 cases in China. Non-small cell lung cancer (NSCLC) comprises the vast majority (85%) of all lung cancers. Epidermal growth factor receptor (EGFR) mutations were reported in about 17% and 50% of lung adenocarcinoma in Caucasians and Asians, respectively. EGFR Exon20ins mutations represent approximately 1%-12% of EGFR mutations in patients with NSCLC.

Reference：

1.International Agency for Research on Cancer (IARC).Cancer Today (iarc.fr). Released December 14, 2022. Accessed May 6, 2023.

2. Fang W, Huang Y, Hong S, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer. 2019;19(1):595.